Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 May 1;81(1):102–109. doi: 10.1097/QAI.0000000000001979

Table 3.

Linear regression analyses of low vs high sCD163 at 6 months following ART initiation (infancy) and school-age neurocognitive and motor scores.

6 mo sCD163 >1100 ng/ml vs ≤1100 ng/ml

Unadjusted Adjusteda
Domain N Mean difference (95% CI) P N Mean difference (95% CI) P
Global cognitive ability 27 −0.45 (−0.90, −0.00) 0.05b 26 −0.42 (−0.86, 0.027) 0.07b
Visual-spatial processing 27 −0.20 (−0.65, 0.26) 0.4 26 −0.17 (−0.63, 0.29) 0.5
Short-term memory 27 −0.63 (−1.31, 0.04) 0.06b 26 −0.52 (−1.12, 0.08) 0.08b
Learning 27 −0.56 (−1.22, 0.11) 0.1b 26 −0.57 (−1.26, 0.12) 0.1b
Delayed memory 21 −0.46 (−1.29, 0.38) 0.3 21 −0.43 (−1.29, 0.43) 0.3
Nonverbal test performance 27 −0.41 (−0.80 to −0.02) 0.04b 26 −0.39 (−0.78, −0.00) 0.05b
Executive function 27 −0.24 (−1.00 to 0.51) 0.5 26 −0.19 (−1.02, 0.62) 0.6
Attention 24 −0.28 (−0.89, 0.34) 0.4 23 −0.31 (−0.89, 0.26) 0.3
Motor 26 0.40 (−0.38, 1.18) 0.3 25 0.42 (-0.37 to 1.20) 0.3

Note, CI, confidence interval.

a

Adjusted for 6-mo. weight-for age Z-score and plasma HIV RNA level.

b

Retained significance using Benjamini Hochberg.